Low physical stability is the main reason limiting the widespread use of amorphous pharmaceuticals.
Introduction
In recent years, amorphous drugs have become the subject of considerable interest due to their favorable properties such as higher apparent solubility, faster dissolution rate, and potentially better bioavailability when compared to their crystalline counterparts. (1) (2) (3) (4) Although the benefits of amorphous pharmaceuticals are unquestionable, it should be pointed out that these materials are thermodynamically unstable. Consequently, during manufacturing or storage they may revert to the crystalline form and lose their superior properties.(5-7) Thus, to fully exploit the advantages given by drugs in the disordered state it is necessary to stabilize them in the amorphous form. (8) Currently, the most effective strategy to suppress devitrification of amorphous active pharmaceutical ingredients (APIs) is to mix them with various excipients. (9) (10) (11) The mechanisms responsible for the stabilization of drugs in binary systems remain still unclear, however it is generally believed that the antiplasticizing effect exerted by an additive as well as the specific molecular interactions between drug and excipient may play crucial roles. (12, 13) Until recently, polymers with high glass transition temperature (Tg) were the most frequently recommended crystallization inhibitors. (14) However, due to the limited solubility of some drugs in polymeric matrix as well as other drawbacks of drug-polymer systems (e.g., difficulties in pulverization or poor compressibility), researchers are trying to find new, more effective stabilizers. (15, 16) Currently, binary amorphous mixtures comprising low-molecular-weight compounds instead of polymers have become the subject of significant interest. (17) (18) (19) Numerous experimental studies have consistently shown that small molecules such as saccharides or other APIs can improve the physical stability of easily recrystalling amorphous pharmaceuticals more effectively than polymers. (20) (21) (22) Allesø et al. and Löbmann et al. reported that even very unstable drugs such as naproxen can be significantly stabilized by using another amorphous pharmaceutical: cimetidine or indomethacin. (23, 24) It should be pointed out that appropriate coamorphous combinations of two drugs can give a lot of benefits. Beyond improving water solubility and physical stability, the second API may improve the therapeutic effect and consequently bring economic advantages: cheaper production associated with smaller quantities of drugs and excipients, one production line, and one packing.
The present study deals with the coamorphous combination of two drugs, i.e., the cholesterollowering ezetimibe (EZB) and indapamid (IDP), that is commonly used for the treatment of hypertension. The binary amorphous EZB-IDP mixture is interesting for multiple reasons. First, such composition may provide a therapeutic advantage in the treatment of combined hypertension and hypercholesterolemia, as medical studies indicate that abnormal lipids and high blood pressure frequently coexist and both are the main risk factors for cardiovascular disease. (25) (26) (27) Second, both EZB and IDP belong to class II drugs according to the Biopharmaceutics Classification System (BCS), which means that their bioavailability is limited due to their low water solubility. (28, 29) Consequently, transformation of these APIs into their amorphous, more soluble forms is expected to enhance their bioavailability. Third, the dosing intervals are very similar for EZB and IDP, i.e., both drugs should be administered once daily, which justifies a need for preparing such binary mixtures. (30, 31) Ultimately, it is anticipated that a suitable stoichiometric combination of EZB with IDP will lead to a high physical stability, which will be beneficial from a manufacturing and storage perspective.
In the present study, binary amorphous mixtures of ezetimib and indapamid in various molar ratios were prepared by quench cooling from the melt. The physicochemical properties of the EZB-IDP compositions were studied by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and FTIR (Fourier transform infrared spectroscopy). Furthermore, the molecular mobility that is generally considered as the main factor governing the physical stability of amorphous materials(32-34) was investigated for mentioned coamorphous drug-drug systems by means of broadband dielectric spectroscopy (BDS). From these results, one can answer the question: how does the IDP content affect the crystallization tendency of binary EZB-IDP mixture? Additionally, the long-term physical stability of EZB-IDP systems was studied by XRD.
Experimental Methods

Materials
Ezetimibe (Mw = 409.4 g/mol) and indapamide (Mw = 365.8 g/mol) drugs of purity greater than 99% were purchased from Polpharma (Starogard Gdański, Poland) and used as received. These were prepared by the quench cooling technique. In order to obtain the homogeneous binary systems prior to the quenching, we have prepared the physical mixtures of these compounds by gentle mixing in a mortar for 5 min. After that we dried these mixtures for 10 min at 373 K to remove the water. This is because the IDP drug that was used in our experiment was hemihydrates. When the samples were dried, the crystalline mixtures were melted in aluminum dishes on a hot plate (CAT M. Zipperer GmbH H 17.5D) at T = 440 K. Time of the sample melting was no longer than 2 min. When the mixtures were fully melted, we vitrified them by fast transfer of the dish from the hot plate to a cold copper plate. The coamorphous binary mixtures of EZB and IDP obtained in the presented way were analyzed immediately after preparation to protect them from moisture.
Differential Scanning Calorimetry (DSC)
Thermodynamic properties of pure EZB, pure IDP, EZB 10:1 IDP, EZB 5:1 IDP, EZB 2:1 IDP, EZB 1:1 IDP, and EZB 1:2 IDP were examined using a Mettler-Toledo DSC 1 STAR e System. The measuring device was calibrated for temperature and enthalpy using zinc and indium standards. The instrument was equipped with an HSS8 ceramic sensor having 120 thermocouples and liquid nitrogen cooling station.
Crystallization as well as melting points were determined as the onset of the peak, whereas the glass transition temperature was determined as the midpoint of the heat capacity increment. The samples were measured in an aluminum crucible (40 μL). All measurements were carried out in the range from 298 to 450 K with a variety-5 K/min or 10 K/min-of heating rates.
To obtain accurate temperature dependences of the heat capacity for pure amorphous EZB, IDP, and their binary mixtures, a stochastic temperature-modulated differential scanning calorimetry (TOPEM) method implemented by Mettler-Toledo TOPEM was employed. These measurements were performed in the temperature range from 300 to 390 K with a heating rate of 0.5 K/min.
Attenuated Total Reflection Fourier Transform Infrared Spectroscopy (ATR-FTIR)
Infrared spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer and evaluated using Spectrum v5.0.1 software. Each spectrum was scanned in the range of 650-4000 cm -1 with a resolution of 4 cm -1 , and a minimum of four scans were collected and averaged in order to obtain good quality spectra. The spectra were normalized and background corrected.
Broadband Dielectric Spectroscopy (BDS)
Dielectric measurements of pure EZB, pure IDP, EZB 10:1 IDP, EZB 5:1 IDP, EZB, EZB 1:1 IDP, and EZB 1:2 IDP were carried out using Novo-Control GMBH Alpha dielectric spectrometer, in the frequency range from 10 -2 Hz to 10 6 Hz at temperatures from 339 to 423 K with step of 2 K. The temperature was controlled by a Quattro temperature controller with temperature stability better than 0.1 K.
Dielectric studies of all samples were performed immediately after fast cooling of the melt in a parallel-plate cell made of stainless steel (diameter 15 mm and a 0.1 mm gap with Teflon spacers).
X-ray Diffraction (XRD)
The X-ray diffraction measurements were performed using a Rigaku-Denki D/MAX RAPID II-R diffractometer equipped with a rotating Ag anode (λKα = 0.5608 Å), an incident beam (002) graphite monochromator, and an image plate in the Debye-Scherrer geometry as a detector. The X-ray beam width at the sample was 0.3 mm. The investigated samples were placed inside glass capillaries with a diameter of 1.5 mm and wall thickness of 0.01 mm. The measurements were carried out for the capillaries filled with samples and empty. The diffraction intensity for the empty capillary was then subtracted. The obtained two-dimensional diffraction patterns were converted into one-dimensional functions of intensity versus the scattering angle using suitable software.
Thermal Properties of Amorphous Mixtures of Ezetimib and Indapamid Drugs
The quench-cooled amorphous EZB has a glass transition temperature of 333.5 K, when measured by using DSC with heating rate of 5 K/min. The DSC thermogram, obtained at this heating rate, exhibits an exothermic peak at 415 K corresponding to the sample cold crystallization (see Figure 1 ). This indicate that pure amorphous EZB reveals quite strong crystallization tendency above Tg. The opposite behavior occurs for the pure amorphous IDP drug, that has Tg almost 40 K higher than that for EZB. In this case, recrystallization processes were not be observed both below and above the glass transition temperature even with a heating rate as slow as 1 K/min. In order to find out how the thermal properties of the mentioned drugs will vary when the drugs are mixed together, five coamorphous mixtures containing various molar ratios of EZB and IDP (EZB-IDP:
10:1, 5:1, 2:1, 1:1, 1:2), have been measured using the DSC technique. All these measurements were carried out over the same temperature range, from 298 to 450 K, and at two different heating rates:
5 K/min and 10 K/min. As can be seen in Figure 1 , the mixtures containing EZB and IDP are characterized by a single glass transition event which moves toward higher temperatures with IDP content. In Figure 1 we can also observed that all coamorphous compositions do not recrystallize when heated 
where w1 and w2 are the weight fractions of each component, and Tg1 and Tg2 correspond to the glass transition temperature of each component. Tg is the glass transition temperature of the mixture, while K is a measure of the interaction between the components, and it can be defined as follows:(39)
ΔCp in eq 2 denotes the change in heat capacity at Tg.
In order to check whether or not the antiplastization effect is the dominant mechanism responsible for better stability of EZB-IDP systems, the theoretical values of glass transition temperature for mixtures of various IDP content have been calculated by using eq 1. The predicted values of Tg were subsequently compared with the experimentally determined data (see Figure 2) . The values of ΔCp, that are required in eq 2, as well as the values of the experimentally derived Tg were taken from stochastic temperature-modulated differential scanning calorimetry (TMDSC) measurements, where the heating rate was equal to 0.5 K/min. In order to confirm the absence of the specific chemical interactions between both mixed drugs we performed a series of FTIR experiments. As it can be seen in Figure 3 and Table 2 The dielectric loss spectra of all examined systems exhibit the same main features: one well-resolved loss peak corresponding to the structural (α) relaxation process as well as dc conductivity. As can be seen, the α-relaxation mode moves toward higher frequencies with heating as well as with increasing of IDP content. Additionally, during heating of the examined samples we do not observe any drop in the intensity of structural relaxation peak that indicates an absence of mixture cold crystallization.
According to the literature reports, pure amorphous EZB drug measured in similar conditions begins to recrystallize at a temperature at which the maximum of the α-relaxation is located at frequency equal to 10 5 Hz (what corresponds to τα = 1.6 μs). (40) In view of the fact that the mixtures do not begin to crystallize at τα ∼ 1.6 μs, one can conclude that the enhancement of the EZB physical stability in binary EZB-IDP mixture is governed not only by a kinetic factor (i.e., molecular mobility) but also by a thermodynamical factor (i.e., configurational entropy, enthalpy, or Gibbs free energy).
From analysis of dielectric loss spectra the temperature dependences of α-relaxation times for all examined coamorphous systems were obtained (see Figure 5a ). To determine the values of τα as well as dc conductivity at various temperatures, the experimental data have been fitted using the HavrilakNegami (HN) function with the dc conductivity term:(41)
where ε∞ is high frequency limit permittivity, ε0 denotes the permittivity of vacuum, Δε is dielectric As can be seen, two distinct linear regions may be observed for all measured samples, confirming the necessity for use of two sets of VFT parameters to describe properly the τα(T) dependences of studied mixtures. The temperature at which the VFT1 and VFT2 intersect (Tcross) as well as all the fitting parameters are collected in Table 3 . Additionally, the VFT1 fits are shown in Figure 5a as solid lines. 
It should be noted that this parameter is of particular interest for the pharmaceutical industry, because it is often used to predict the tendency of disordered materials toward recrystallization. (54) In the literature the fragility parameter is reported to vary from 16 to 200. But, in the case of APIs, the typical mp values range between 60 and 120. The compounds characterized by a low value of steepness index are classified as strong materials, whereas a large value of mp corresponds to fragile systems. According to the two order parameter (TOP) model proposed by Tanaka, strong materials are expected to be more physically stable than fragile materials. (55) This is because they have stronger frustration against crystallization. This frustration of the system results from the competition between long and short ordering existing in any liquids. Long-range ordering is responsible for nucleation and crystal growth, while short-range ordering is associated with formation of the local favored structures that have no crystallographic symmetry. As illustrated in Figure 6 , the fragility parameter decreases continuously with increasing IDP content. This result suggests that the physical stability of the examined mixtures should improve with increasing IDP concentration. Since our measurements do not reveal crystallization of coamorphous compositions containing EZB and IDP, the trend of stability has been checked at elevated temperature (T = 398 K) by means of DSC (see Figure 7) . These experiments show that the mixture crystallization slows down with increasing IDP content (exothermic peak is shifted to higher times), which proves that the fragility parameter indeed reflects the physical stability of the examined systems. 
Long-Term Physical Stability Studies of EZB-IDP Coamorphous Mixtures
As it was indicated by both BDS and DSC data, the coamorphous mixtures containing EZB and IDP drugs are characterized by greater physical stability than the pure EZB. Naturally, the questions arise:
what is the minimal amount of IDP guaranteeing appropriate physical stability of the amorphous EZB?
and consequently, how long we can safely store these compositions at room temperature? In order to answer these questions we have performed time dependent isothermal XRD studies for all As can be seen, the X-ray diffraction patterns for the initially amorphous compounds are characterized by broad amorphous halos which confirm that in the investigated samples there were no threedimensional long-range ordered structures. This finding indicates that the tested systems just after preparation were fully amorphous. After 21 days of storage small and sharp crystalline peaks might be observed only on the EZB XRD pattern, proving that a small portion of amorphous EZB recrystallized (Dc = 15%). Others systems, after the same period of time, remained unchanged, and their degree of crystallization was equal to zero. Interestingly, even after 72 days, all investigated EZB-IDP mixtures were still physically stable, i.e., we did not observe any Bragg peaks in XRD patterns.
The XRD studies show that mixtures containing EZB and IDP are characterized by high physical stability.
Even a small amount of IDP drug (8.8 wt %) is able to suppress the EZB's recrystallization for at least 72 days, when the mixture is stored at 297 K. It should be noted that, from a medical point of view, the best seems to be EZB-IDP mixture containing 11.1 to 33.3 wt % of IDP. Since these values are higher than 8.8 wt % of IDP, it is obvious that such binary compositions will be very stable.
Conclusions
In this article the coamorphous binary mixture of ezetimib and indapamide was investigated by using differential scanning calorimetry, broadband dielectric spectroscopy, and X-ray diffraction. We found that the simple quench cooling method can be applied for the production of homogeneous composition of these two pharmaceuticals. Thermal analysis of mixtures characterized by various molar ratios of EZB and IDP indicated that the glass transition temperature (Tg) rises with increasing IDP content in accordance with the Gordon-Taylor equation. This result suggests that improvement of the physical stability of highly unstable amorphous EZB drug in binary mixture is mainly caused by an antiplasticizing effect exerted by IDP.
The effect of IDP on the molecular dynamics of amorphous EZB in their coamorphous compositions was investigated over a broad temperature and frequency range by using dielectric spectroscopy.
These experiments have shown that, besides an antiplasticizing effect, an additional factor is also responsible for the physical stability improvement of the measured mixtures. Based on dielectric data we determined the mp and βKWW parameters that characterize the structural relaxation process. These parameters are generally considered as a measure of the physical stability of systems in disordered state. A low value of fragility parameter and a narrow α-relaxation peak (i.e., high value of βKWW) correspond to high stability. Our studies have shown that the mp parameter indeed reflects the tendency to recrystallization of coamorphous binary EZB-IDP mixtures. However, such a correlation was not observed in the case of βKWW. The shape of the structural relaxation loss peak is fixed for mixtures with different concentrations of EZB-IDP drugs. The value of βKWW parameter for all tested binary systems as well as for pure amorphous EZB is equal to 0.7. Using XRD techniques we also examined the long-term physical stability of binary mixtures that contain EZB and IDP drugs. These measurements have proven that even a small amount of IDP drug (8.8 wt %) may significantly suppress the devitrification of amorphous EZB drug: after 60 days the tested mixture was fully amorphous. As a consequence the coamorphous binary ezetimib-indapamid system is a very promising candidate for new formulations intended for combined therapy. Apart from the medical and economic benefits of using these drugs together in amorphous forms, such a binary composition provides high physical stability that is essential for further commercial application.
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